Efficacy and safety of different doses and retreatment of rituximab: A randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

Annals of the Rheumatic Diseases

Volumn 69, Issue 9, 2010, Pages 1629-1635

  Emery, Paul ^a   Deodhar, A ^b   Rigby, W F ^c   Isaacs, J D ^d   Combe, B ^e   Racewicz, A J ^f   Latinis, K ^g   Abud Mendoza, C ^h   Szczepanski L J ⁱ   Roschmann, R A ^j   Chen, A ^k   Armstrong, G K ^l   Douglass, W ^l   Tyrrell, H ^l  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e LAPEYRONIE HOSPITAL   (France)

^f Regional Hospital of Bialystok   (Poland)

^g UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^h UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

ⁱ Wydz Fizjoterapii   (Poland)

^j Advanced Musculoskeletal Institute   (United States)

^k GENENTECH INC   (United States)

^l ROCHE PRODUCTS LTD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PLACEBO; RITUXIMAB; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAPHORESIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; INFECTION; INJECTION SITE REACTION; LETHARGY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PANCREAS CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RETREATMENT; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THROAT IRRITATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; UTERINE CERVIX CARCINOMA; VASCULAR DISEASE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77955896561     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.119933     Document Type: Article

References (12)

1. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81. (Pubitemid 38758544)
2. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
3. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
4. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
5. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60. (Pubitemid 23102493)
6. Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics 2004;22(Suppl 1):27-38.
7. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-92.
8. Cella D, Yount S, Sorensen M, et al. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005;32:811-19.
9. Mease PJ, Revicki DA, Szechinski J, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the Dose- Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. J Rheumatol 2008;35:20-30.
10. Tak PP, Rigby WFC, Rubbert-Roth A, et al. Rituximab in combination with methotrexate (MTX) significantly inhibits joint damage and improves clinical outcomes in patients with early active RA who are naïve to MTX: a randomized, active comparator placebo-controlled trial (IMAGE). Arthritis Rheum 2009;60(Suppl 10):S238, Abstract 636.
11. Tak PP, Cohen SB, Emery P, et al. Clinical response following the first treatment course with rituximab: effect of baseline autoantibody status (RF, anti-CCP). Ann Rheum Dis 2007;66(Suppl II):338.
12. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-908.